Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | MAOA | P21397 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | DAPK1 | P53355 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10789834 | 1.00 | MAPT (0.40) | MAPTMAOAMEN1KMT2AALDH1A1 | |
| SCHEMBL11424649 | 0.89 | MAOA (0.46) | MAPTMAOAMEN1KMT2AALDH1A1 | |
| SCHEMBL27321737 | 0.87 | MEN1 (0.42) | MAPTMAOAMEN1KMT2AALDH1A1 | |
| SCHEMBL20218226 | 0.86 | ADORA2A (0.41) | MAPTMAOAMEN1KMT2AALDH1A1 | |
| SCHEMBL11395596 | 0.84 | EGFR (0.51) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL20978592 | 0.84 | EGFR (0.46) | MAPTMAOAMAPK1TDP1L3MBTL1 | |
| SCHEMBL22873368 | 0.84 | EGFR (0.51) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL20978609 | 0.84 | EGFR (0.46) | MAPTMAOAMAPK1TDP1L3MBTL1 | |
| SCHEMBL22845122 | 0.84 | MAPT (0.38) | MAPTMAOAMEN1KMT2AALDH1A1 | |
| SCHEMBL10907239 | 0.83 | BCL2 (0.43) | MAPTMAOAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0129044-A1 | Synthesis of (+)-4-demethoxydaunomycinone | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1984-12-27 | — | — | EP | claimed |
| US-4489206-A | Synthesis of (+)-4-demethoxydaunomycinone | ADRIA LABORATORIES, INC. (US) | 1984-12-18 | — | — | US | claimed |
| US-4448724-A | Synthesis of 4-demethoxydaunomycinone | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1984-05-15 | — | — | US | claimed |
| US-20260140106-A1 | COMPOUNDS FOR TREATMENT OF DISEASES AND METHODS OF SCREENING THEREFOR | MAX PLANCK GES ZUR FORDERUNG DER WISSENSCHENFTEN E V (DE) | 2026-05-21 | — | — | US | disclosed |
| US-12422427-B2 | Compounds for treatment of diseases and methods of screening therefor | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-09-23 | — | — | US | disclosed |
| EP-3473630-B1 | BORON-BASED PRODRUG STRATEGY FOR INCREASED BIOAVAILABILITY AND LOWER-DOSAGE REQUIREMENTS FOR DRUG MOLECULES CONTAINING AT LEAST ONE PHENOL (OR AROMATIC HYDROXYL) GROUP | XAVIER UNIV OF LOUISIANA (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200150107-A1 | COMPOUNDS FOR TREATMENT OF DISEASES AND METHODS OF SCREENING THEREFOR | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-05-14 | — | — | US | disclosed |
| WO-2020078924-A1 | COMPOUNDS FOR TREATMENT OF DISEASES AND METHODS OF SCREENING THEREFOR | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-04-23 | — | — | WO | disclosed |
| US-8105477-B2 | System and method for electrochemical detection of biological compounds | HANDYLAB, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110039345-A1 | SYSTEM AND METHOD FOR ELECTROCHEMICAL DETECTION OF BIOLOGICAL COMPOUNDS | HANDYLAB, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-7820030-B2 | System and method for electrochemical detection of biological compounds | HANDYLAB, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20060207891-A1 | System and method for electrochemical detection of biological compounds | HANDYLAB, INC. (US) | 2006-09-21 | — | — | US | disclosed |
| EP-0107486-B1 | AMINONAPHTHACENE DERIVATIVES AND THEIR PRODUCTION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-04-29 | — | — | EP | disclosed |
| EP-0129044-A1 | Synthesis of (+)-4-demethoxydaunomycinone | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1984-12-27 | — | — | EP | disclosed |
| US-4489206-A | Synthesis of (+)-4-demethoxydaunomycinone | ADRIA LABORATORIES, INC. (US) | 1984-12-18 | — | — | US | disclosed |
| US-4448724-A | Synthesis of 4-demethoxydaunomycinone | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1984-05-15 | — | — | US | disclosed |
| US-4448724-A | Synthesis of 4-demethoxydaunomycinone | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1984-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260140106-A1 | COMPOUNDS FOR TREATMENT OF DISEASES AND METHODS OF SCREENING THEREFOR | DLD, ECHS1, LIPA | MAPT 121/4885MAOA 1816/4885MEN1 1931/4885 |
| US-12422427-B2 | Compounds for treatment of diseases and methods of screening therefor | HADH, ECHS1, DLD | MAPT 499/4885MAOA 2384/4885MEN1 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.